Galectin Therapeutics (GALT) says new clinical trial data disclosed Thursday suggest its experimental cancer drug improves the efficacy of Merck’s blockbuster immunotherapy therapy Keytruda when the two drugs are used together to treat patients with advanced melanoma.

No, the new Galectin data — what little there are — show no such thing. It’s more reasonable to conclude these new data show Galectin’s drug to be a placebo.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!

GET STARTED

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • This article is so biased and incorrect it boggles the imagination.

    This study is an Investigator-initiated trial by Portland Providence Cancer Center, one of the leading Cancer Immunotherapy research centers in the United States.

    Here is what Dr. Brendan Curti, the lead researcher, said of the results:
    MD-02 used in combination with KEYTRUDA and to measure the response rate to combined therapy. “We are very encouraged by the objective response rate and the disease control rate observed in patients with advanced melanoma. These response rates were higher than expected with KEYTRUDA alone,” said Dr. Curti. “An objective response rate of seven out of fourteen patients (50%) and a disease control rate of nine out of fourteen patients (64%) with advanced melanoma is very encouraging. The published objective response rates in randomized studies using KEYTRUDA in patients with advanced melanoma range from 21% in patients who have had prior therapy to 39% in patients who had not received prior systemic therapy. Importantly, the combination was also very well tolerated, and treatment appears to be associated with fewer adverse events than expected with KEYTRUDA alone.”

    He also said: Dr. Curti states “the response rates observed overall in advanced melanoma and head and neck cancer patients were better than expected with KEYTRUDA alone and are the basis for moving forward with both tumor types, particularly given the low response rates of anti-PD-1 monotherapy in head and neck cancer. There is a significant clinical need for better options for these patients and our initial objective response rates were encouraging enough to warrant inclusion of additional patients to help determine whether we should also pursue these challenging patient populations in a phase 2 trial. Taken together with the observed favorable safety and tolerability of the combination, these results provide a compelling rationale to move forward with this approach.

    The Cohort 3 patients were treated with a higher dose of GR-MD-02 (8 mg/kg) than those in the Cohort 2 trial (4 mg/kg). Based on the findings of Cohort 3 further trials will utilize the 4 mg/kg dose because it appears to be more effective.

    Fact is fact, fiction is fiction. This article is pure fiction authored by someone with a motive to bury Galectin Therapeutics; readers should do their own investigation and make up their own minds rather than rely on the fiction presented here

    • If there was any motive to bury Galectin Therapeutics here, your dissenting view wouldn’t be published directly underneath. You have just cut and pasted text from the company press release. If you want to base your investment decisions purely on company PR, I wish you the best of luck. The rest of us prefer to explore other points of view. The points you missed, or ignored, here are that the cohorts and overall numbers are too small to derive any conclusion that the combination is better than Keytruda alone, and that there is no evidence of a dose response.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy